CRPA1A2
/ CorreGene
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
July 17, 2026
A first-in-human phase I study evaluating the safety, tolerability, and preliminary antitumor activity of CRPA1A2, a HLA-A*02:01-restricted MAGE-A1-targeting T cell engager, in patients with advanced solid tumors
(ESMO 2026)
- No abstract available
Clinical • First-in-human • Metastases • P1 data • Oncology • Solid Tumor • HLA-A
1 to 1
Of
1
Go to page
1